Clinical significance and biological roles of CRKL in human bladder carcinoma

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4101-4106

  Han, Bin ^a   Luan, Lan ^b   Xu, Zhenqun ^a   Wu, Bin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG MEDICAL COLLEGE   (China)

Author keywords

Bladder cancer; CRKL; ERK; Proliferation

Indexed keywords

CRK LIKE PROTEIN; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; CCND1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; BIOLOGICAL FUNCTIONS; BLADDER; BLADDER CARCINOMA; CANCER CELL LINE; CCK8 ASSAY; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION ASSAY; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TRANSWELL ASSAY; UPREGULATION; WESTERN BLOTTING; BLADDER TUMOR; CHEMISTRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PHOSPHORYLATION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84902969177     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1536-y     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10-29.
2. Liang PY, Li HY, Zhou ZY, Jin YX, et al. Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma. Tumour Biol. 2013;34:1783-91.
3. Tian F, Xu F, Zhang ZY, Ge JP, et al. Expression of CHD1L in bladder cancer and its influence on prognosis and survival. Tumour Biol. 2011;34:3687-90.
4. Sapre, N, Anderson PD, Costello AJ, Hovens CM, et al., Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? Urol Oncol. 2013 Oct 17. pii: S1078-1439(13)00289-5. doi: 10.1016/j.urolonc.2013.07.002. [Epub ahead of print]
5. Sanchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 2012;33:347-61.
6. Shan GY, Zhang Z, Chen QG, Yu XY, et al. Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. Tumour Biol. 2012;33:847-55.
7. Atkins CD, Wrzesinski SH. Radiotherapy plus chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2010;367:380. author reply 380-1.
8. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, et al. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood. 1994;84:1731-6. (Pubitemid 24286120)
9. ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene. 1993;8:2469-74. (Pubitemid 23252376)
10. Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene. 2001;20:6348-71. (Pubitemid 32977844)
11. Zhao T, Miao Z, Wang Z, Xu Y, et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol. 2013;34:2891-7.
12. Singer CF, Hudelist G, Lamm W, Mueller R, et al. Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep. 2006;15:353-9.
13. Kim YH, Kwei KA, Girard L, Salari K, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2009;29:1421-30.
14. Ladanyi M. CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be? Cancer Discov. 2011;1:560-1.
15. Wang Y, Dong QZ, Fu L, Stoecker M, et al. Overexpression of Crkl correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog. 2011;52:890-9.
16. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98:629-35. (Pubitemid 46563437)
17. Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38:217-22.
18. Fristrup N, Birkenkamp-Demtroder K, Reinert T, Sanchez-Carbayo M, et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 2013;182:339-49.
19. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-47. (Pubitemid 39626217)
20. Webb CP, Van Aelst L, Wigler MH, Vande Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci U S A. 1998;95:8773-8. (Pubitemid 28350564)
21. Arai A, Aoki M, Weihua Y, Jin A, et al. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. Cell Signal. 2006;18:2162-71. (Pubitemid 44636158)
22. Xu YY, Mao XY, Song YX, Zhao F, et al. Midkine confers adriamycin resistance in human gastric cancer cells. Tumour Biol. 2012;33:1543-8.
23. Hu L, Xia L, Zhou H, Wu B, et al. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCalpha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol. 2002;34:2573-81.
24. Lee EJ, Lee SJ, Kim S, Cho SC, et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-kappaB/AP-1 pathway: involvement of the p21WAF1 expression. Cell Signal. 2013;25:2025-38.
25. Yang C, Klein EA, Assoian RK, Kazanietz MG. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Biochem J. 2008;410:167-75. (Pubitemid 351300336)
26. Dong QZ, Wang Y, Tang ZP, Fu L, et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013;182:954-64.